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Abstract
Background: The malignant form of atrophic papulosis (Köhlmeier-Degos disease) is a rare thrombo-occlusive
vasculopathy that can affect multiple organ systems. Patients typically present with distinctive skin lesions reflective
of vascular drop out. The small bowel is the most common internal organ involved, resulting in considerable
morbidity and mortality attributable to ischemic microperforations. Determination of the presence of
gastrointestinal lesions is critical in distinguishing systemic from the benign, cutaneous only disease and in
identifying candidates for treatment.
Case presentation: We describe an 18 year old male who first presented with cutaneous atrophic papulosis but
became critically ill from small bowel microperforations. He had an almost immediate and dramatic response to
treatment. Prior to his presentation with acute abdomen he had upper and lower endoscopy showing areas of
nonspecific patchy erythema. At laparotomy, innumerable characteristic lesions with central pearly hue and
erythematous border were seen. PubMed was used for a literature search using the keywords malignant atrophic
papulosis, Degos disease, endoscopy, laparoscopy and laparotomy. This search yielded 200 articles which were
further analyzed for diagnostic procedures and findings.
Among the 200 articles we identified only 11 cases in which endoscopy was performed. Results of endoscopy and
laparotomy in our patient with malignant atrophic papulosis were compared to those in the literature. Endoscopy
of the gastrointestinal tract has shown gastritis and non-specific inflammation whereas laparoscopy shows white
plaques with red borders on the serosal surface of the small bowel and the peritoneum. From personal
communications with other physicians worldwide, we identified three additional unpublished cases in which
endoscopy revealed only minimal changes while laparoscopy showed dramatic lesions. From our experience the
endoscopic findings are often subtle and nonspecific, whereas laparascopy or laparotomy will reveal pathognomic
lesions on the serosal surface of the intestine.
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Conclusion: Our report contrasts the endoscopic and laparoscopic findings in malignant atrophic papulosis which
suggest laparoscopy is the more powerful means of detecting gastrointestinal involvement. Imaging studies may
serve as a key indicator of systemic progression. Based on our experience, laparoscopy should be performed when
there is a high index of suspicion for gastrointestinal malignant atrophic papulosis, even if endoscopic examination
is non-diagnostic or normal.
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Background
Atrophic papulosis (Köhlmeier-Degos disease) is a rare
thrombo-occlusive vasculopathy that can affect multiple
organ systems. Patients primarily present with distinctive
skin lesions reflective of vascular drop out. The small
bowel is the most common internal organ involved,
resulting in considerable morbidity and mortality attrib-
utable to ischemic microperforations [1–3]. Skin lesions
associated with atrophic papulosis appear as avascular,
slightly depressed porcelain-like lesions with a telangi-
ectatic rim [3]. The more common cutaneous manifesta-
tions of a primary vasculopathy, ulceration, livedo and
palpable purpura, are not seen. Gastrointestinal (GI) in-
volvement develops approximately 60 % of the time,
usually one to three years after the skin lesions first ap-
pear [4]. The skin and GI lesions show striking similar-
ities on gross examination even though the caliber of the
affected vessels is different. In the skin, the targeted ves-
sels are capillaries and venules of the dermis, whereas in
the gastrointestinal tract subserosal arteries and arteri-
oles are the primary target. While both vascular lesions
result in a similar depressed porcelain scar, the nature of
the vasculopathy histologically is different. In the skin
the primary vascular pattern is a thrombogenic microan-
giopathy while in the gut, an obliterative mucinous
fibrointimal arteriopathy is seen [4, 5]. Until recently, re-
ported cases of systemic disease have been descriptions
of an inexorable path to a fatal outcome [2]. Reports of
prominent C5b-9 deposits in skin and gastrointestinal
tissue of patients with the malignant form of atrophic
papulosis (MAP) have led to the use of eculizumab, an
inhibitor of C5 activation, with prolonged survival in
some cases [1]. Additionally, a recent report suggests the
efficacy of treprostinil as adjunctive therapy in patients
with MAP [2].
New hypotheses to the pathogenesis of MAP suggests
two forms of vasculopathy which are mechanistically
distinctive and have helped identify new treatment op-
tions. One aspect is a thrombotic microangiopathy at-
tributable to endothelial cell injury. Prior studies have
shown extensive vascular deposits of C5b-9 as the basis of
injury analogous to other catastrophic C5b-9 mediated
microvascular injury syndromes such as atypical hemolytic
uremic syndrome [6]. Eculizumab has an almost immedi-
ate effect, preventing further formation and deposition of
the membrane attack complex, thereby decreasing C5b-9
stimulated apoptosis. It also immediately inhibits forma-
tion of the anphylatoxin C5a [1]. This particular microan-
giopathy is also associated with a type I interferon rich
microenvironment as revealed by extensive vascular de-
position of myxovirus protein, a surrogate marker of type
I interferons [6, 7]. Deficiency of endothelial progenitor
cells (EPC) is one hypothesis in the pathogenesis of MAP.
EPC exposed to interferon-alpha induce the up-regulation
of IL-18 and caspase-1. IL-18 inhibits vascular repair while
caspase-1 contributes to EPC dysfunction. In essence
there is an imbalance between vascular damage and vas-
cular repair. Eculizumab has no effect on the interferon-
mediated injury. Recent data suggest treprostinil, a prosta-
cyclin analog that facilitates healing of ischemic tissue and
inhibits platelet aggregation, could ameliorate symptoms
and signs of MAP by virtue of its effect on enhancing EPC
repair [1, 2, 8]. Because of this, treprostinil has been
employed as adjunctive therapy in patients with MAP [9].
Determination of the presence of gastrointestinal le-
sions is critical. Untreated, individuals with such lesions
will have progressive disease culminating in repeated
bowel perforations and death. At present, there is no
consensus on the best means of detecting gastrointes-
tinal lesions in patients with cutaneous atrophic
papulosis.
Case presentation
We describe an 18 year old male who presented with cu-
taneous atrophic papulosis but became critically ill from
small bowel microperforations. We also describe his sis-
ter, who developed similar skin lesions compatible with
a familial variant. PubMed was used for a literature
search using the keywords malignant atrophic papulosis,
Degos disease, endoscopy, laparoscopy and laparotomy.
The search yielded 200 articles which were further
analyzed for diagnostic procedures and findings. Also
personal communications with other physicians caring
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for individuals with systemic MAP led to evaluation and
comparison of gastrointestinal imaging modalities.
Patient One: Patient One is an 18 year old male who
presented with cutaneous disease, had rapidly proliferat-
ing skin lesions over a course of a year, and then sur-
vived small bowel microperforations from MAP (Fig. 1).
Two months prior to his presentation with acute abdo-
men, lower endoscopy showed patchy erythematous mu-
cosa with central clearing at the sigmoid, rectosigmoid
colon and splenic flexure (Fig. 2). Upper endoscopy
demonstrated mild acute gastritis. At laparotomy,
innumerable typical lesions of 0.3-0.5 cm papules with
central pearly hue and erythematous border were seen
(Fig. 3). The patient had a very rapid and dramatic re-
sponse to therapy with eculizumab [10]. Later on the
patient required a second agent, treprostinil, for main-
tenance and suppression of other systemic manifesta-
tions. Five years have passed and he has been doing well
on double therapy of eculizumab and treprostinil.
Patient Two: Patient Two is the sister of Patient One.
She slowly developed a small number of cutaneous le-
sions that were biopsied and were consistent with atro-
phic papulosis. She had minor gastrointestinal
discomfort. For this reason and due to her brother's his-
tory a laparoscopy was performed with normal findings.
Her abdominal discomfort spontaneously resolved.
Given the lack of GI findings and the highly limited na-
ture of the cutaneous presentation she is less likely to
progress to systemic MAP.
Personal communications
Patient A: A 44 year old female with cutaneous lesions
of atrophic papulosis developed sudden monocular vi-
sion loss and severe eye pain requiring enucleation with
pathologic findings of microvascular changes in the orbit
consistent with MAP. Colonoscopy in April 2012
showed normal findings but exploratory laparoscopy in
October 2012 revealed innumerable MAP lesions
(Fig. 4).
Patient B: A 36 year old male with MAP overlapping
with dermatomyositis had a colonoscopy showing only
nonspecific ischemic colitis and a CT scan demonstrated
colitis and enteritis but then developed microperfora-
tions with lesions typical of MAP noted at time of sur-
gery [11].
Patient C: A patient in Malaysia had nonspecific endos-
copy and normal colonoscopy but striking laparoscopic
changes.
Patient D: A previously reported 43 year old male pa-
tient had a normal CT scan and repetitive endoscopic bi-
opsies and a colonoscopy that were unremarkable but
after development of acute abdomen, a resected portion
of bowel showed extensive subserosal fibrobliterative
arteriopathic and thrombotic microvascular disease diag-
nostic of MAP [1] (Figs. 5, 6, 7, 8, 9).
Patient E: This previously reported patient was 36 years
old male with dermatomyositis who presented with clas-
sic skin lesions of atrophic papulosis. He then developed
severe gastrointestinal symptoms. While endoscopy and
Fig. 1 Patient one’s rapidly proliferating skin lesions
Fig. 2 Patient one, lower endoscopy showed patchy erythematous
mucosa with central clearing at the sigmoid, rectosigmoid colon
and splenic flexure
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CT scan were unremarkable, laparoscopy revealed classic
lesions of MAP. The patient died of sepsis [12].
Among the 200 cases that were reviewed we found 11 in
which endoscopy was performed. Results of endoscopy
and laparotomy in our patients with MAP were analyzed
and compared to those in the literature. Based on the
published cases, 9 out of the 11 endoscopies performed
had non-specific endoscopic changes either prior to or
near-simultaneous to catastrophic bowel perforation [9,
10, 13]. Laparotomy findings are striking and predictably
present in those with acute abdomen. In the cases found
in the literature and in our Patient One, endoscopic
evaluation revealed pearly-rose patches with a surround-
ing hyperemic rim in the mucosa which may be inter-
preted as general inflammation. Findings are most
commonly seen in the small bowel, especially jejunum,
but can involve any part of the gastrointestinal lumen.
More pathognomic findings are found at laparoscopy,
and are characterized by multiple white plaques with red
borders involving the serosal surface of the small bowel
and the peritoneum [14, 15]. Laparoscopic lesions are
similar to the skin lesions seen in patients with MAP
[10]. The gross serosal porcelain plaques in concert with
the normal endoscopic findings are well exemplified by
the pathology of resection specimens in patients with
MAP. In particular in patients with an acute abdomen
necessitating bowel resection, the cardinal hallmarks are
an intact mucosa with mild inflammation or no inflam-
mation in concert with striking obliterative arteriopathic
changes most conspicuous in subserosal vessels but also
Fig. 3 Patient one, at laparotomy, innumerable typical lesions of 0.3–0.5 cm papules with central pearly hue and erythematous border were seen
Fig. 4 Patient A, colonoscopy was normal but exploratory laparoscopy revealed innumerable MAP lesions
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showing variable involvement within the submucosal.
Concomitant subserosal inflammation and edema may
be seen. The end sequelae is an ischemic one character-
ized by a severe necrotizing serositis.
Conclusions
Historically, death in patients with MAP has most com-
monly resulted from gastrointestinal microperforations
and subsequent sepsis. Our experience successfully treat-
ing Patient One led us to investigate means of early
detection of gastrointestinal involvement. Early interven-
tion with effective therapy could prevent progression to
bowel perforation. At present, available therapies are
most often initiated as an act of desperation in patients
who are already critically ill with advanced multiorgan
failure.
Extensive and rapidly progressive skin lesions are more
likely to be associated with the early development of sys-
temic disease. We believe any such individual, even if
asymptomatic, and any individual with cutaneous atro-
phic papulosis and unexplained abdominal pain should
undergo laparoscopy as the best means of detecting
gastrointestinal involvement.
Due to the rarity of MAP, diagnostic guidelines were
only recently presented [3], while therapeutic ones do
not exist. When patients present with acute abdomen,
findings at laparotomy or laparoscopy are always strik-
ing. Previously published cases of MAP have reported
Fig. 5 This low power view shows a relatively normal appearing
colonic mucosa however the subserosa appears very edematous
Fig. 6 Higher power magnification demonstrates a normal
appearing colonic mucosa despite severe inflammatory and vascular
pathology involving the serosal surface and subserosa
Fig. 7 Within the subserosa and to a lesser extent the submucosa, an
arteriopathy exhibiting varying stages of inflammation and fibro-
obliterative healing is identified. In this photomicrograph, the
endothelium appears activated and is detached from the intima
compatible with primary endothelial cell injury. As part of the
acute response, there is an endoluminal influx of inflammatory
cells especially macrophages. Note the red cell engulgment, a
finding indicative of macrophage activation
Fig. 8 In this subserosal vessel, there is still the residuum of an
inflammatory endothelialitis however there is progressive
intimal fibrosis
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time to death after detection of systemic disease to be
one to two years [3, 16]. Patient One, however, is cur-
rently a 5 year survivor of severe systemic MAP. With
the evolution of therapies that have altered the previ-
ously grim prognosis, pursuing early detection of sys-
temic disease is essential in more consistently improving
disease outcome.
Endoscopic evaluation has been suggested for all pa-
tients with classic skin lesions of atrophic papulosis with
specific or nonspecific symptomatology on the central or
peripheral nervous system, gastrointestinal tract or any
other organ system [3]. Unfortunately since the jejunum
is the most commonly involved section of the gastro-
intestinal tract and because the vascular lesion is primar-
ily subserosal and not mucosal [4], endoscopic
evaluation can and has given false negative results. Cap-
sule endoscopy can be added to the workup to provide
additional imaging of the jejunum but, again, the view is
mucosal and the pathology is subserosal. Our experience
suggests laparoscopy is a more sensitive diagnostic tool
that should be implemented on higher risk patients [13].
High risk patients include those whose skin lesions are
proliferating rapidly and any with unexplained gastro-
intestinal symptoms [3, 17–19]. CT scanning of the ab-
domen is also an insensitive method of detection of
enteric involvement of MAP [20]. Laparoscopy may un-
cover systemic involvement in an otherwise asymptom-
atic patient with only cutaneous lesions [21]. MAP like
many autoinflammatory conditions is a targeted organ
and site specific disease exhibiting a peculiar and dis-
tinctive predilection to involve select small arteries and
arterioles of the subserosa with relative sparing of the
microvasculature of the lamina propria.
After 5 years of close observation of Patient One we
believe we have identified strategies for early detection
with laparoscopy as a potential lifesaving tool. GI in-
volvement with symptoms such as dyspepsia, abdominal
pain, nausea, vomiting and others should be further in-
vestigated in MAP patients. While the gastrointestinal
tract can be examined by endoscopy, to look for white,
yellowish, or pearly-rose patches with a hyperemic rim
[14] the changes may be subtle and can be easily missed
using this method [13, 18]. Laparoscopy can more effect-
ively identify the diagnostic lesions of gastrointestinal
MAP [13, 14]. Laparoscopic identification of white spots
with hyperemic borders on the serosal surface of the
bowel and the peritoneum are diagnostic of MAP and
do not require a biopsy. Their identification should war-
rant immediate treatment [1, 2, 9, 13]. From our litera-
ture search we do not recommend serosal biopsy of the
lesions since it can lead to seromuscular breach [4, 22].
These findings can help patients obtain faster and eas-
ier access to treatments as they emerge. Since clear diag-
nostic and treatment guidelines for MAP do not exist
and untreated systemic MAP has a fatal prognosis, there
is need to identify patients at risk for GI microperfora-
tions, sepsis, and death. Our experience and the other
cases we report such that visualization of the serosa of
the bowel and peritoneum by laparoscopy is superior to
endoscopic evaluation. Prospective studies are necessary
to clarify the role of both endoscopy and laparoscopy in
the detection of systemic disease in patients with cutane-
ous atrophic papulosis and to establish the frequency
with which such studies should be repeated in those in
whom the findings are negative.
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Fig. 9 In this subserosal vessel the vascular lumen is now occluded
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Degos disease. The subsequent ischemia leads to compromise of
the bowel, eventuating in transmural infarction. The latter reflects
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the microcirculation of the remainder of the bowel
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